<svg aria-roledescription="flowchart-v2" role="graphics-document document" viewBox="0 0 273.828125 878" style="max-width: 273.828px; background-color: white;" class="flowchart" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" width="100%" id="my-svg"><style>#my-svg{font-family:"trebuchet ms",verdana,arial,sans-serif;font-size:16px;fill:#333;}@keyframes edge-animation-frame{from{stroke-dashoffset:0;}}@keyframes dash{to{stroke-dashoffset:0;}}#my-svg .edge-animation-slow{stroke-dasharray:9,5!important;stroke-dashoffset:900;animation:dash 50s linear infinite;stroke-linecap:round;}#my-svg .edge-animation-fast{stroke-dasharray:9,5!important;stroke-dashoffset:900;animation:dash 20s linear infinite;stroke-linecap:round;}#my-svg .error-icon{fill:#552222;}#my-svg .error-text{fill:#552222;stroke:#552222;}#my-svg .edge-thickness-normal{stroke-width:1px;}#my-svg .edge-thickness-thick{stroke-width:3.5px;}#my-svg .edge-pattern-solid{stroke-dasharray:0;}#my-svg .edge-thickness-invisible{stroke-width:0;fill:none;}#my-svg .edge-pattern-dashed{stroke-dasharray:3;}#my-svg .edge-pattern-dotted{stroke-dasharray:2;}#my-svg .marker{fill:#333333;stroke:#333333;}#my-svg .marker.cross{stroke:#333333;}#my-svg svg{font-family:"trebuchet ms",verdana,arial,sans-serif;font-size:16px;}#my-svg p{margin:0;}#my-svg .label{font-family:"trebuchet ms",verdana,arial,sans-serif;color:#333;}#my-svg .cluster-label text{fill:#333;}#my-svg .cluster-label span{color:#333;}#my-svg .cluster-label span p{background-color:transparent;}#my-svg .label text,#my-svg span{fill:#333;color:#333;}#my-svg .node rect,#my-svg .node circle,#my-svg .node ellipse,#my-svg .node polygon,#my-svg .node path{fill:#ECECFF;stroke:#9370DB;stroke-width:1px;}#my-svg .rough-node .label text,#my-svg .node .label text,#my-svg .image-shape .label,#my-svg .icon-shape .label{text-anchor:middle;}#my-svg .node .katex path{fill:#000;stroke:#000;stroke-width:1px;}#my-svg .rough-node .label,#my-svg .node .label,#my-svg .image-shape .label,#my-svg .icon-shape .label{text-align:center;}#my-svg .node.clickable{cursor:pointer;}#my-svg .root .anchor path{fill:#333333!important;stroke-width:0;stroke:#333333;}#my-svg .arrowheadPath{fill:#333333;}#my-svg .edgePath .path{stroke:#333333;stroke-width:2.0px;}#my-svg .flowchart-link{stroke:#333333;fill:none;}#my-svg .edgeLabel{background-color:rgba(232,232,232, 0.8);text-align:center;}#my-svg .edgeLabel p{background-color:rgba(232,232,232, 0.8);}#my-svg .edgeLabel rect{opacity:0.5;background-color:rgba(232,232,232, 0.8);fill:rgba(232,232,232, 0.8);}#my-svg .labelBkg{background-color:rgba(232, 232, 232, 0.5);}#my-svg .cluster rect{fill:#ffffde;stroke:#aaaa33;stroke-width:1px;}#my-svg .cluster text{fill:#333;}#my-svg .cluster span{color:#333;}#my-svg div.mermaidTooltip{position:absolute;text-align:center;max-width:200px;padding:2px;font-family:"trebuchet ms",verdana,arial,sans-serif;font-size:12px;background:hsl(80, 100%, 96.2745098039%);border:1px solid #aaaa33;border-radius:2px;pointer-events:none;z-index:100;}#my-svg .flowchartTitleText{text-anchor:middle;font-size:18px;fill:#333;}#my-svg rect.text{fill:none;stroke-width:0;}#my-svg .icon-shape,#my-svg .image-shape{background-color:rgba(232,232,232, 0.8);text-align:center;}#my-svg .icon-shape p,#my-svg .image-shape p{background-color:rgba(232,232,232, 0.8);padding:2px;}#my-svg .icon-shape rect,#my-svg .image-shape rect{opacity:0.5;background-color:rgba(232,232,232, 0.8);fill:rgba(232,232,232, 0.8);}#my-svg .label-icon{display:inline-block;height:1em;overflow:visible;vertical-align:-0.125em;}#my-svg .node .label-icon path{fill:currentColor;stroke:revert;stroke-width:revert;}#my-svg :root{--mermaid-font-family:"trebuchet ms",verdana,arial,sans-serif;}#my-svg .default&gt;*{fill:#f9f9f9!important;stroke:#333!important;stroke-width:2px!important;}#my-svg .default span{fill:#f9f9f9!important;stroke:#333!important;stroke-width:2px!important;}#my-svg .highlight&gt;*{fill:#e6f7ff!important;stroke:#0077be!important;stroke-width:3px!important;}#my-svg .highlight span{fill:#e6f7ff!important;stroke:#0077be!important;stroke-width:3px!important;}</style><g><marker orient="auto" markerHeight="8" markerWidth="8" markerUnits="userSpaceOnUse" refY="5" refX="5" viewBox="0 0 10 10" class="marker flowchart-v2" id="my-svg_flowchart-v2-pointEnd"><path style="stroke-width: 1; stroke-dasharray: 1, 0;" class="arrowMarkerPath" d="M 0 0 L 10 5 L 0 10 z"/></marker><marker orient="auto" markerHeight="8" markerWidth="8" markerUnits="userSpaceOnUse" refY="5" refX="4.5" viewBox="0 0 10 10" class="marker flowchart-v2" id="my-svg_flowchart-v2-pointStart"><path style="stroke-width: 1; stroke-dasharray: 1, 0;" class="arrowMarkerPath" d="M 0 5 L 10 10 L 10 0 z"/></marker><marker orient="auto" markerHeight="11" markerWidth="11" markerUnits="userSpaceOnUse" refY="5" refX="11" viewBox="0 0 10 10" class="marker flowchart-v2" id="my-svg_flowchart-v2-circleEnd"><circle style="stroke-width: 1; stroke-dasharray: 1, 0;" class="arrowMarkerPath" r="5" cy="5" cx="5"/></marker><marker orient="auto" markerHeight="11" markerWidth="11" markerUnits="userSpaceOnUse" refY="5" refX="-1" viewBox="0 0 10 10" class="marker flowchart-v2" id="my-svg_flowchart-v2-circleStart"><circle style="stroke-width: 1; stroke-dasharray: 1, 0;" class="arrowMarkerPath" r="5" cy="5" cx="5"/></marker><marker orient="auto" markerHeight="11" markerWidth="11" markerUnits="userSpaceOnUse" refY="5.2" refX="12" viewBox="0 0 11 11" class="marker cross flowchart-v2" id="my-svg_flowchart-v2-crossEnd"><path style="stroke-width: 2; stroke-dasharray: 1, 0;" class="arrowMarkerPath" d="M 1,1 l 9,9 M 10,1 l -9,9"/></marker><marker orient="auto" markerHeight="11" markerWidth="11" markerUnits="userSpaceOnUse" refY="5.2" refX="-1" viewBox="0 0 11 11" class="marker cross flowchart-v2" id="my-svg_flowchart-v2-crossStart"><path style="stroke-width: 2; stroke-dasharray: 1, 0;" class="arrowMarkerPath" d="M 1,1 l 9,9 M 10,1 l -9,9"/></marker><g class="root"><g class="clusters"/><g class="edgePaths"><path marker-end="url(#my-svg_flowchart-v2-pointEnd)" style="" class="edge-thickness-normal edge-pattern-solid edge-thickness-normal edge-pattern-solid flowchart-link" id="L_preclinical_phase1_0" d="M136.914,86L136.914,92.167C136.914,98.333,136.914,110.667,136.914,122.333C136.914,134,136.914,145,136.914,150.5L136.914,156"/><path marker-end="url(#my-svg_flowchart-v2-pointEnd)" style="" class="edge-thickness-normal edge-pattern-solid edge-thickness-normal edge-pattern-solid flowchart-link" id="L_phase1_phase2_0" d="M136.914,238L136.914,246.167C136.914,254.333,136.914,270.667,136.914,286.333C136.914,302,136.914,317,136.914,324.5L136.914,332"/><path marker-end="url(#my-svg_flowchart-v2-pointEnd)" style="" class="edge-thickness-normal edge-pattern-solid edge-thickness-normal edge-pattern-solid flowchart-link" id="L_phase2_phase3_0" d="M136.914,414L136.914,420.167C136.914,426.333,136.914,438.667,136.914,450.333C136.914,462,136.914,473,136.914,478.5L136.914,484"/><path marker-end="url(#my-svg_flowchart-v2-pointEnd)" style="" class="edge-thickness-normal edge-pattern-solid edge-thickness-normal edge-pattern-solid flowchart-link" id="L_phase3_fda_approval_0" d="M136.914,566L136.914,572.167C136.914,578.333,136.914,590.667,136.914,602.333C136.914,614,136.914,625,136.914,630.5L136.914,636"/><path marker-end="url(#my-svg_flowchart-v2-pointEnd)" style="" class="edge-thickness-normal edge-pattern-solid edge-thickness-normal edge-pattern-solid flowchart-link" id="L_fda_approval_phase4_0" d="M136.914,718L136.914,724.167C136.914,730.333,136.914,742.667,136.914,754.333C136.914,766,136.914,777,136.914,782.5L136.914,788"/></g><g class="edgeLabels"><g transform="translate(136.9140625, 123)" class="edgeLabel"><g transform="translate(-98.5703125, -12)" class="label"><foreignObject height="24" width="197.140625"><div style="display: table-cell; white-space: nowrap; line-height: 1.5; max-width: 200px; text-align: center;" class="labelBkg" xmlns="http://www.w3.org/1999/xhtml"><span class="edgeLabel"><p>Approval for Human Testing</p></span></div></foreignObject></g></g><g transform="translate(136.9140625, 287)" class="edgeLabel"><g transform="translate(-100, -24)" class="label"><foreignObject height="48" width="200"><div style="display: table; white-space: break-spaces; line-height: 1.5; max-width: 200px; text-align: center; width: 200px;" class="labelBkg" xmlns="http://www.w3.org/1999/xhtml"><span class="edgeLabel"><p>Evaluating Therapeutic Effectiveness</p></span></div></foreignObject></g></g><g transform="translate(136.9140625, 451)" class="edgeLabel"><g transform="translate(-84.3359375, -12)" class="label"><foreignObject height="24" width="168.671875"><div style="display: table-cell; white-space: nowrap; line-height: 1.5; max-width: 200px; text-align: center;" class="labelBkg" xmlns="http://www.w3.org/1999/xhtml"><span class="edgeLabel"><p>Confirmation of Efficacy</p></span></div></foreignObject></g></g><g transform="translate(136.9140625, 603)" class="edgeLabel"><g transform="translate(-67.140625, -12)" class="label"><foreignObject height="24" width="134.28125"><div style="display: table-cell; white-space: nowrap; line-height: 1.5; max-width: 200px; text-align: center;" class="labelBkg" xmlns="http://www.w3.org/1999/xhtml"><span class="edgeLabel"><p>Regulatory Review</p></span></div></foreignObject></g></g><g transform="translate(136.9140625, 755)" class="edgeLabel"><g transform="translate(-76.0390625, -12)" class="label"><foreignObject height="24" width="152.078125"><div style="display: table-cell; white-space: nowrap; line-height: 1.5; max-width: 200px; text-align: center;" class="labelBkg" xmlns="http://www.w3.org/1999/xhtml"><span class="edgeLabel"><p>Long-term Monitoring</p></span></div></foreignObject></g></g></g><g class="nodes"><g transform="translate(136.9140625, 47)" id="flowchart-preclinical-0" class="node default default"><rect height="78" width="238.5625" y="-39" x="-119.28125" style="fill:#f9f9f9 !important;stroke:#333 !important;stroke-width:2px !important" class="basic label-container"/><g transform="translate(-89.28125, -24)" style="" class="label"><rect/><foreignObject height="48" width="178.5625"><div style="display: table-cell; white-space: nowrap; line-height: 1.5; max-width: 200px; text-align: center;" xmlns="http://www.w3.org/1999/xhtml"><span class="nodeLabel"><p>Preclinical Testing<br /><small>Laboratory and animal studies</small></p></span></div></foreignObject></g></g><g transform="translate(136.9140625, 199)" id="flowchart-phase1-1" class="node default default"><rect height="78" width="257.828125" y="-39" x="-128.9140625" style="fill:#f9f9f9 !important;stroke:#333 !important;stroke-width:2px !important" class="basic label-container"/><g transform="translate(-98.9140625, -24)" style="" class="label"><rect/><foreignObject height="48" width="197.828125"><div style="display: table-cell; white-space: nowrap; line-height: 1.5; max-width: 200px; text-align: center;" xmlns="http://www.w3.org/1999/xhtml"><span class="nodeLabel"><p>Phase 1 Trials<br /><small>Small group of healthy volunteers</small></p></span></div></foreignObject></g></g><g transform="translate(136.9140625, 375)" id="flowchart-phase2-2" class="node default default"><rect height="78" width="201.53125" y="-39" x="-100.765625" style="fill:#f9f9f9 !important;stroke:#333 !important;stroke-width:2px !important" class="basic label-container"/><g transform="translate(-70.765625, -24)" style="" class="label"><rect/><foreignObject height="48" width="141.53125"><div style="display: table-cell; white-space: nowrap; line-height: 1.5; max-width: 200px; text-align: center;" xmlns="http://www.w3.org/1999/xhtml"><span class="nodeLabel"><p>Phase 2 Trials<br /><small>Larger group of patients</small></p></span></div></foreignObject></g></g><g transform="translate(136.9140625, 527)" id="flowchart-phase3-3" class="node default default"><rect height="78" width="216.34375" y="-39" x="-108.171875" style="fill:#f9f9f9 !important;stroke:#333 !important;stroke-width:2px !important" class="basic label-container"/><g transform="translate(-78.171875, -24)" style="" class="label"><rect/><foreignObject height="48" width="156.34375"><div style="display: table-cell; white-space: nowrap; line-height: 1.5; max-width: 200px; text-align: center;" xmlns="http://www.w3.org/1999/xhtml"><span class="nodeLabel"><p>Phase 3 Trials<br /><small>Large-scale patient testing</small></p></span></div></foreignObject></g></g><g transform="translate(136.9140625, 679)" id="flowchart-fda_approval-4" class="node default highlight"><rect height="78" width="209.671875" y="-39" x="-104.8359375" style="fill:#e6f7ff !important;stroke:#0077be !important;stroke-width:3px !important" class="basic label-container"/><g transform="translate(-74.8359375, -24)" style="" class="label"><rect/><foreignObject height="48" width="149.671875"><div style="display: table-cell; white-space: nowrap; line-height: 1.5; max-width: 200px; text-align: center;" xmlns="http://www.w3.org/1999/xhtml"><span class="nodeLabel"><p>FDA Approval<br /><small>Review and authorization</small></p></span></div></foreignObject></g></g><g transform="translate(136.9140625, 831)" id="flowchart-phase4-5" class="node default default"><rect height="78" width="223.71875" y="-39" x="-111.859375" style="fill:#f9f9f9 !important;stroke:#333 !important;stroke-width:2px !important" class="basic label-container"/><g transform="translate(-81.859375, -24)" style="" class="label"><rect/><foreignObject height="48" width="163.71875"><div style="display: table-cell; white-space: nowrap; line-height: 1.5; max-width: 200px; text-align: center;" xmlns="http://www.w3.org/1999/xhtml"><span class="nodeLabel"><p>Phase 4 Trials<br /><small>Post-marketing surveillance</small></p></span></div></foreignObject></g></g></g></g></g></svg>